European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Work -

Monograph 0478 defines tablets as solid preparations containing a single dose of one or more active substances. They are primarily produced by compressing particles but can also be made through extrusion or freeze-drying (oral lyophilisates). This general monograph covers various categories, including: . Gastro-resistant and Modified-release Tablets . Effervescent, Soluble, and Dispersible Tablets .

Monograph 0478 begins by defining precisely what constitutes a "tablet." According to the Ph. Eur., tablets are solid dosage forms containing one or more active substances, with or without excipients, obtained by compressing uniform volumes of particles. The monograph explicitly covers a wide range of tablet types, including uncoated, film-coated, gastro-resistant (enteric-coated), and dispersible tablets. Importantly, it also addresses sublingual, buccal, and effervescent tablets, highlighting the versatility of the dosage form.

No more than one individual mass can fall outside 85%–115% of the average mass, and none can fall outside 75%–125%. Standard Quality Tests European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

: Measured in Newtons, typically on a sample of 10 tablets to determine the force required for disruption.

Which from Monograph 0478 you are targeting (e.g., immediate-release, modified-release, orodispersible)? Gastro-resistant and Modified-release Tablets

The European Pharmacopoeia Monograph for Tablets (0478) is far more than a technical document; it is a sophisticated quality management tool. By mandating tests for uniformity, disintegration, dissolution, and mechanical strength, it transforms a simple compressed powder into a predictable, safe, and effective medicine. It protects patients from dose dumping, poor absorption, and fragile products, while providing manufacturers with clear, legally enforceable specifications. As pharmaceutical science advances—towards personalized doses, 3D-printed tablets, and complex modified-release profiles—Monograph 0478 will continue to be revised and expanded. Yet its core mission remains unchanged: to ensure that every tablet, whether taken in a London hospital or a rural pharmacy in Greece, meets the highest possible standard of quality. In doing so, Ph. Eur. 0478 exemplifies the very essence of pharmacopoeial science: trust through testing.

: Manufacturers must take rigorous preventative measures to prevent contamination during processing, storage, and cross-border distribution, adhering directly to the guidelines set in Ph. Eur. General Chapter 5.1 . and cross-border distribution

Required to disintegrate within 5 minutes in cold water. 3. Dissolution

Dissolution testing evaluates the rate at which the API is released from the tablet matrix into a liquid medium, simulating human physiological conditions. This is a critical surrogate marker for in vivo drug absorption and bioavailability. Modified-release and gastro-resistant tablets require highly specialized dissolution profiles (e.g., testing in acid medium followed by a buffer change). C. Disintegration (2.9.1)